 Matthew Wicklund
Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscular Dystrophies, Limb-Girdle | 9 | 2023 | 12 | 3.300 |
Why?
| | Muscle Proteins | 6 | 2018 | 219 | 1.390 |
Why?
| | Myositis, Inclusion Body | 4 | 2023 | 11 | 1.110 |
Why?
| | Muscle, Skeletal | 7 | 2022 | 1515 | 0.840 |
Why?
| | Muscular Dystrophy, Duchenne | 5 | 2022 | 80 | 0.830 |
Why?
| | Amyotrophic Lateral Sclerosis | 3 | 2018 | 62 | 0.790 |
Why?
| | Muscular Dystrophies | 4 | 2014 | 36 | 0.780 |
Why?
| | Myasthenic Syndromes, Congenital | 1 | 2018 | 2 | 0.670 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2016 | 192 | 0.500 |
Why?
| | Environmental Exposure | 2 | 2011 | 405 | 0.500 |
Why?
| | Prednisone | 4 | 2022 | 235 | 0.410 |
Why?
| | Membrane Proteins | 3 | 2014 | 1055 | 0.370 |
Why?
| | Muscular Diseases | 2 | 2023 | 107 | 0.370 |
Why?
| | Immunosuppressive Agents | 3 | 2019 | 681 | 0.350 |
Why?
| | Mutation, Missense | 2 | 2018 | 300 | 0.280 |
Why?
| | Middle Aged | 16 | 2021 | 27617 | 0.240 |
Why?
| | Humans | 33 | 2023 | 118974 | 0.230 |
Why?
| | Proteostasis Deficiencies | 1 | 2023 | 7 | 0.230 |
Why?
| | Adult | 16 | 2023 | 31512 | 0.230 |
Why?
| | Valosin Containing Protein | 2 | 2023 | 6 | 0.220 |
Why?
| | Muscular Dystrophy, Facioscapulohumeral | 1 | 2022 | 15 | 0.210 |
Why?
| | Male | 20 | 2023 | 57801 | 0.210 |
Why?
| | Pregnenediones | 2 | 2022 | 21 | 0.200 |
Why?
| | Dystrophin | 2 | 2020 | 30 | 0.200 |
Why?
| | Nortriptyline | 1 | 2021 | 4 | 0.200 |
Why?
| | Duloxetine Hydrochloride | 1 | 2021 | 9 | 0.200 |
Why?
| | Rare Diseases | 2 | 2019 | 113 | 0.190 |
Why?
| | Polyneuropathies | 1 | 2021 | 50 | 0.190 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 187 | 0.180 |
Why?
| | Braces | 1 | 2019 | 24 | 0.180 |
Why?
| | Social Participation | 1 | 2019 | 12 | 0.180 |
Why?
| | Disease Progression | 3 | 2023 | 2490 | 0.180 |
Why?
| | Ankle | 1 | 2019 | 71 | 0.170 |
Why?
| | Analgesics | 1 | 2021 | 159 | 0.170 |
Why?
| | Biopsy | 3 | 2019 | 1079 | 0.170 |
Why?
| | Mobility Limitation | 1 | 2019 | 62 | 0.170 |
Why?
| | Pyridostigmine Bromide | 1 | 2018 | 5 | 0.170 |
Why?
| | Myositis | 1 | 2019 | 41 | 0.170 |
Why?
| | Neuronal Outgrowth | 1 | 2018 | 10 | 0.170 |
Why?
| | Oxidoreductases | 1 | 2019 | 100 | 0.170 |
Why?
| | Cholinesterase Inhibitors | 1 | 2018 | 26 | 0.170 |
Why?
| | Receptor, IGF Type 1 | 1 | 2018 | 59 | 0.160 |
Why?
| | Osteitis Deformans | 1 | 2018 | 5 | 0.160 |
Why?
| | Charcot-Marie-Tooth Disease | 1 | 2018 | 19 | 0.160 |
Why?
| | Dysferlin | 3 | 2014 | 6 | 0.160 |
Why?
| | Headache Disorders | 1 | 2018 | 12 | 0.160 |
Why?
| | Homozygote | 1 | 2018 | 190 | 0.160 |
Why?
| | Pain Management | 1 | 2021 | 294 | 0.160 |
Why?
| | Female | 15 | 2023 | 61565 | 0.160 |
Why?
| | Glucocorticoids | 1 | 2022 | 545 | 0.150 |
Why?
| | Propofol | 1 | 2018 | 49 | 0.150 |
Why?
| | Mutation | 3 | 2018 | 3457 | 0.150 |
Why?
| | Checklist | 1 | 2018 | 81 | 0.150 |
Why?
| | Aged | 11 | 2021 | 19657 | 0.150 |
Why?
| | Parkinson Disease | 2 | 2019 | 334 | 0.150 |
Why?
| | Steroids | 1 | 2018 | 153 | 0.150 |
Why?
| | Multicenter Studies as Topic | 1 | 2018 | 253 | 0.150 |
Why?
| | Hypnotics and Sedatives | 1 | 2018 | 136 | 0.150 |
Why?
| | Phenotype | 6 | 2023 | 3003 | 0.140 |
Why?
| | Myoglobinuria | 1 | 2016 | 2 | 0.140 |
Why?
| | Activities of Daily Living | 1 | 2019 | 354 | 0.140 |
Why?
| | Myasthenia Gravis | 1 | 2016 | 19 | 0.140 |
Why?
| | Complement Membrane Attack Complex | 1 | 2016 | 35 | 0.140 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 398 | 0.140 |
Why?
| | Staining and Labeling | 1 | 2016 | 146 | 0.140 |
Why?
| | Glycogen Storage Disease Type II | 1 | 2015 | 7 | 0.130 |
Why?
| | Young Adult | 7 | 2021 | 10793 | 0.130 |
Why?
| | Endoscopy | 1 | 2018 | 272 | 0.130 |
Why?
| | Immunoglobulin G | 1 | 2019 | 788 | 0.130 |
Why?
| | Methotrexate | 1 | 2016 | 227 | 0.130 |
Why?
| | Double-Blind Method | 4 | 2023 | 1687 | 0.130 |
Why?
| | Research Design | 2 | 2018 | 969 | 0.130 |
Why?
| | Nuclear Proteins | 1 | 2019 | 597 | 0.130 |
Why?
| | Age of Onset | 2 | 2014 | 467 | 0.120 |
Why?
| | Autoantibodies | 2 | 2019 | 1335 | 0.120 |
Why?
| | Quadriceps Muscle | 1 | 2015 | 101 | 0.120 |
Why?
| | Lung Diseases, Interstitial | 1 | 2019 | 464 | 0.120 |
Why?
| | Adolescent | 9 | 2022 | 18480 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 969 | 0.120 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2018 | 814 | 0.110 |
Why?
| | Quality of Life | 1 | 2021 | 2366 | 0.100 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2009 | 15 | 0.090 |
Why?
| | Dura Mater | 1 | 2009 | 29 | 0.090 |
Why?
| | Genotype | 2 | 2006 | 1882 | 0.090 |
Why?
| | Athletic Injuries | 1 | 2016 | 495 | 0.090 |
Why?
| | Environment | 1 | 2011 | 346 | 0.090 |
Why?
| | Child | 6 | 2022 | 19129 | 0.080 |
Why?
| | Arm | 1 | 2009 | 106 | 0.080 |
Why?
| | Treatment Outcome | 5 | 2021 | 9342 | 0.080 |
Why?
| | Child, Preschool | 5 | 2022 | 9491 | 0.070 |
Why?
| | Spinal Cord | 1 | 2009 | 367 | 0.070 |
Why?
| | Range of Motion, Articular | 2 | 2019 | 369 | 0.070 |
Why?
| | Exercise | 1 | 2016 | 1657 | 0.070 |
Why?
| | Muscle Strength | 2 | 2019 | 283 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2021 | 6561 | 0.070 |
Why?
| | Signal Transduction | 1 | 2018 | 4709 | 0.060 |
Why?
| | Infant | 1 | 2018 | 8293 | 0.060 |
Why?
| | Pentosyltransferases | 1 | 2003 | 3 | 0.060 |
Why?
| | Prospective Studies | 3 | 2020 | 6471 | 0.060 |
Why?
| | Genes, Dominant | 1 | 2003 | 96 | 0.060 |
Why?
| | Genes, Recessive | 1 | 2003 | 73 | 0.060 |
Why?
| | Dystroglycans | 2 | 2016 | 7 | 0.050 |
Why?
| | Leg | 1 | 2003 | 234 | 0.050 |
Why?
| | Pregabalin | 1 | 2021 | 10 | 0.050 |
Why?
| | Mexiletine | 1 | 2021 | 7 | 0.050 |
Why?
| | Muscle Weakness | 1 | 2021 | 82 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2021 | 132 | 0.050 |
Why?
| | Orthotic Devices | 1 | 2019 | 30 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 7 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2021 | 252 | 0.040 |
Why?
| | Role | 1 | 2019 | 32 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2020 | 123 | 0.040 |
Why?
| | Neuralgia | 1 | 2021 | 120 | 0.040 |
Why?
| | Muscle Contraction | 1 | 2022 | 413 | 0.040 |
Why?
| | Mycophenolic Acid | 1 | 2019 | 79 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 344 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 159 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2019 | 190 | 0.040 |
Why?
| | Foot | 1 | 2019 | 106 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1419 | 0.040 |
Why?
| | Gene Deletion | 1 | 2020 | 361 | 0.040 |
Why?
| | Contracts | 1 | 2018 | 9 | 0.040 |
Why?
| | Budgets | 1 | 2018 | 14 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 344 | 0.040 |
Why?
| | Mice, Inbred ICR | 1 | 2018 | 111 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2022 | 3174 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 4708 | 0.040 |
Why?
| | Ankle Joint | 1 | 2019 | 159 | 0.040 |
Why?
| | Respiratory Function Tests | 1 | 2019 | 526 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 177 | 0.040 |
Why?
| | Research Support as Topic | 1 | 2018 | 114 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2017 | 61 | 0.040 |
Why?
| | Proteins | 1 | 2003 | 938 | 0.040 |
Why?
| | Pedigree | 1 | 2018 | 485 | 0.040 |
Why?
| | Protein Transport | 1 | 2018 | 412 | 0.040 |
Why?
| | Animals | 3 | 2023 | 33381 | 0.040 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 274 | 0.040 |
Why?
| | Vital Capacity | 1 | 2017 | 260 | 0.040 |
Why?
| | Receptors, Cholinergic | 1 | 2016 | 46 | 0.040 |
Why?
| | United States | 3 | 2023 | 12555 | 0.040 |
Why?
| | Walking | 1 | 2019 | 415 | 0.030 |
Why?
| | Patient Compliance | 1 | 2019 | 537 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 296 | 0.030 |
Why?
| | Recovery of Function | 1 | 2019 | 604 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2017 | 280 | 0.030 |
Why?
| | Canada | 1 | 2016 | 340 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 736 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1691 | 0.030 |
Why?
| | Mice | 2 | 2023 | 15520 | 0.030 |
Why?
| | Qualitative Research | 1 | 2019 | 953 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1795 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 676 | 0.030 |
Why?
| | Registries | 1 | 2021 | 1810 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2513 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2017 | 610 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2018 | 2680 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 693 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4596 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1384 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3057 | 0.020 |
Why?
| | Spinal Cord Compression | 1 | 2009 | 18 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2436 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2275 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2674 | 0.020 |
Why?
| | Magnetic Resonance Angiography | 1 | 2009 | 210 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6412 | 0.020 |
Why?
| | Caveolin 1 | 1 | 2006 | 23 | 0.020 |
Why?
| | Calpain | 1 | 2006 | 54 | 0.020 |
Why?
| | Radiography | 1 | 2009 | 861 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2006 | 278 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2006 | 381 | 0.020 |
Why?
| | Creatine Kinase | 1 | 2003 | 75 | 0.010 |
Why?
| | Blotting, Western | 1 | 2006 | 1194 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 12978 | 0.010 |
Why?
|
|
Wicklund's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|